| WXIBF Stock | | | USD 1.86 0.00 0.00% |
President
Dr. Weichang Zhou serves as Senior Vice President, Chief Technology Officer, Executive Director of the Company. Dr. Zhou was appointed as an executive Director, chief technology officer and senior vice president in May 2016, November 2016 and April 2015, respectively. He is primarily responsible for overseeing the development and manufacturing of biologics. He joined the Group in December 2012 as the vice president, responsible for the management of biologics development and manufacturing. Prior to joining the Group, Dr. Zhou served as a senior director of Genzyme Corporation from March 2008 to December 2012, and was responsible for commercial cell culture process development. From October 2002 to February 2008, Dr. Zhou served as a senior director of PDL BioPharma Inc., a biopharmaceutical company listed on NASDAQ, and was responsible for process sciences and engineering functions. From May 1994 to October 2002, Dr. Zhou served as up to an associate director of Merck, and was responsible for fermentation and cell culture process development since 2016.
| Age | 59 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 86 510 8183 1205 |
| Web | https://www.wuxibiologics.com |
Zhou obtained a bachelor’s degree in chemical engineering from Jiangxi University of Technology in the PRC in July 1982. He also obtained a Ph.D. degree in chemical engineering and biotechnology from University of Hannover in Germany in June 1989.
WuXi Biologics Management Efficiency
The company has return on total asset
(ROA) of
0.0551 % which means that it generated a profit of $0.0551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.123 %, meaning that it generated $0.123 on every $100 dollars invested by stockholders. WuXi Biologics' management efficiency ratios could be used to measure how well WuXi Biologics manages its routine affairs as well as how well it operates its assets and liabilities.
WuXi Biologics has accumulated 640.51
M in total debt with debt to equity ratio
(D/E) of 0.12, which may suggest the company is not taking enough advantage from borrowing. WuXi Biologics has a current ratio of 2.25, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist WuXi Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, WuXi Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like WuXi Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for WuXi to invest in growth at high rates of return. When we think about WuXi Biologics' use of debt, we should always consider it together with cash and equity.
WuXi Biologics Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the Peoples Republic of China, North America, Europe, and internationally. The company was incorporated in 2014 and is headquartered in Wuxi, China. Wuxi Biologics is traded on OTC Exchange in the United States. WuXi Biologics [WXIBF] is a
Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.
Management Performance
WuXi Biologics Leadership Team
Elected by the shareholders, the WuXi Biologics' board of directors comprises two types of representatives: WuXi Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of WuXi. The board's role is to monitor WuXi Biologics' management team and ensure that shareholders' interests are well served. WuXi Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, WuXi Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| He Wang, VP Officer | |
| Eileen Wang, IR Senior Director | |
| Weichang Zhou, Senior Vice President CTO, Executive Director | |
| Ming Tu, CFO VP | |
| Li Xiong, VP HR | |
| Ge Li, Non-Executive Chairman of the Board | |
| Jijie Gu, Ex Officer | |
| Zhisheng Chen, CEO, Executive Director | |
| Cong JD, VP Department | |
| Tang MBA, Operations, Communications | |
WuXi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is WuXi Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in WuXi Pink Sheet
WuXi Biologics financial ratios help investors to determine whether WuXi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in WuXi with respect to the benefits of owning WuXi Biologics security.